|
PET Scan in Patients with Neurocardiologic Disorders Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on PET Scan in Patients with Neurocardiologic Disorders conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. PET Scan in Patients with Neurocardiologic Disorders Clinical research trials and PET Scan in Patients with Neurocardiologic Disorders medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including PET Scan in Patients with Neurocardiologic Disorders. PET Scan in Patients with Neurocardiologic Disorders Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a PET Scan in Patients with Neurocardiologic Disorders clinical trial. Participants oftentimes recieve the finest healthcare available for their PET Scan in Patients with Neurocardiologic Disorders condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > PET Scan in Patients with Neurocardiologic Disorders  PET Scan in Patients with Neurocardiologic Disorders
PET Scan in Patients with Neurocardiologic Disorders
For Condition: Autonomic Nervous System Disease,Hypertension,Tachycardia,Vasovagal Syncope
Status: No longer recruiting
Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) ,
Synopsis: This study is designed to use PET scans in order to measure activity of the sympathetic nervous system. The sympathetic nervous system is the portion of the nervous system that maintains a normal supply of blood and fuel to organs during stressful situations. PET scan or Positron Emission Tomography is an advanced form of an X-ray. It is used to detect radioactive substances in the body. During this study researchers plan to inject small amounts of the radioactive drug fluorodopamine into patients. Fluorodopamine is very similar to the chemicals found in the sympathetic nervous system. It can attach to sympathetic nerve endings and allow researchers to view them with the aid of a PET scan. One area of the body with many sympathetic nerve endings is the heart. After giving a dose of fluorodopamine, researchers will be able to visualize all of the sympathetic nerve endings involved in the activity of the heart. In addition, this diagnostic test will help researchers detect abnormalities of the nervous system of patient's hearts.
Details: This project applies positron emission tomographic (PET) scanning after administration of 6-[18F]fluorodopamine ([18F]-6F-DA) to visualize sympathetic innervation and function in patients with neurocardiologic disorders. Patients undergo infusion of [18F]-6F-DA, followed by PET scanning of one or more body regions. Patients may also undergo PET scanning after administration of [13N]-ammonia, to assess regional perfusion; regional blood sampling (including sampling from the coronary sinus or great cardiac vein) during infusion of [3H]-l-norepinephrine ([3H]-NE), to assess the kinetics and metabolism of NE; or magnetic resonance imaging (MRI) to delineate the ventricular myocardium. PET scanning after [18F]-6F-DA administration, in conjunction with other clinical assessment tools, should provide comprehensive information about regional sympathoneural innervation and function in neurocardiologic disorders.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: The subjects are adult patients in one of the following diagnostic categories: coronary heart disease or chest pain and normal coronary arteries; myocardial dysfunction or failure; hypertension; or dysautonomia. Groups of appropriately matched healthy volunteers are studied concurrently as controls. EXCLUSION CRITERIA: Minors are excluded. Subjects in whom anatomic factors complicate vascular access are excluded. Subjects who are not expected clinically to tolerate recumbency during the procedures are excluded. Pregnant or lactating women are excluded. Cardiology patients may be tested while off their usual medications. In this situation, the patients will be inpatients on the cardiology ward, managed clinically by staff of the Cardiology Branch, DIR, NHLBI. Hypertensives will be tested afer having discontinued anti-hypertensive medications for up to two weeks. Patients who must take medications continually in the following categories are excluded: anticoagulants, tricyclic antidepressants, barbiturates, aspirin, acetaminophen. Patients unable to discontinue nicotine or alcohol temporarily are excluded.
Total Enrollment: 335
Location and Contact Information:
National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 940186; 94-N-0186
Study Start Date: July 28, 1994
Record last reviewed: August 4, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001418
Other Vasovagal Syncope Studies:
1. Segregation/Linkage Analysis for Hypertension
2. Epidemiology of Stress and the Metabolic Syndrome
3. INTERMAP: International Population Study on Macronutrients and BP
4. Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients
5. Vascular Effects of Endothelium-Derived Versus Hemoglobin-Transported Nitric Oxide in Healthy Subjects
Related Studies:
Other Vasovagal Syncope Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
PET Scan in Patients with Neurocardiologic Disorders
|
|
|
|
|
|
|
|
